What is the role of dolutegravir (Tivicay) in the treatment of HIV infection?

Updated: Jul 27, 2020
  • Author: Shelley A Gilroy, MD, FACP, FIDSA; Chief Editor: Michael Stuart Bronze, MD  more...
  • Print

A new INSTI, dolutegravir (Tivicay), was approved by the FDA in August 2013 for treatment of HIV-1 infection in combination with other antiretroviral agents in adults and children aged 12 years or older who weigh at least 40 kg. Approval was based on several studies showing evidence of virologic suppression in both treatment-naive and treatment-experienced patients on a daily regimen of the drug. [124, 125, 126, 127] Approval of dolutegravir for the indication in children aged 12 years or older was based on data in integrase-naïve patients.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!